According to an article on the GLOBOCAN statistics of incidence and mortality of cancers worldwide, “cervical cancer is the fourth most frequently diagnosed cancer and the fourth leading cause of cancer death in women” (p. 231, Sung et al., 2021). Cervical cancer results from the growth of abnormal cells in the lining of the cervix. The two most preventative methods used to the reduce the number of cervical cancer diagnosis are immunisation against HPV and cervical screening tests. Regular screening tests can help detect cancer before symptoms appear, making it easier to treat and increases the chances of survival. Although successful screening programs exist in high-income countries like the UAE, disparities remain among certain populations. Specifically for women from lower socio-economic backgrounds and migrants identified as a subgroup with lower cervical screening uptake.
Our recent study found that Emirati and non-Emirati women in Ras Al Khaimah also have low participation rates with pap tests (38.3%) and cervical screening tests (29.7%). In 2018, the UAE Ministry of Health and Prevention reported that approximately 50% of women aged 25-64 participated in cervical cancer screenings. However, the participation rate varied significantly across different emirates, ranging from 16% to 70%.
Several barriers that prevent women’s access to screening services have been identified. The two main factors are individual factors and factors associated with healthcare providers and systems. For instance, one’s lack of knowledge about cervical cancer and screenings or feelings of shame and stigma about screenings are individual factors. Issues such as the physician’s lack of sensitivity and limited availability of pre-booked appointments and clinic hours are healthcare provider factors.
Current interventions
In the UAE, the Pap smear and HPV vaccine is available for sexually active women. For the Pap smear, it is recommended that women aged 25–49 are tested every three years and women aged 50–65 are tested every five years. The HPV vaccine is available to women aged 13–26 years. Despite availability, cervical screening rates in the UAE remain low – 13.9% for mammogram and 28.0% for Pap smear. Therefore, future recommendations are discussed below.
Future recommendations
Based on the findings of our recent study, several policy recommendations can be implemented to improve cervical cancer screening rates among women in Ras Al Khaimah.
The UAE has limited specialised units and trained surgeons for gynaecologic oncology, and therefore access to services is limited. To improve patient care, an increase in dedicated units and training is recommended.
To conclude, a multilevel strategy is needed to combat cervical cancer in Ras Al Khaimah and the larger UAE. Cervical cancer diagnosis can be reduced by raising awareness, removing cultural obstacles, and offering easily accessible screening programs. The cornerstone of our joint battle against cervical cancer in Ras Al Khaimah and beyond continues to be early detection.
References:
Sung, H., Ferlay, J., Siegel, R.L., Laversanne, M., Soerjomatarum, I., Jemal, A., & Bray, F. (2021). Global cancer statistics 2020: Globocan estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer Journal for Clinicians, 71(3), 209-249. https://doi.org/10.3322/caac.21660